Jones Trading Rates Definium Therapeutics (DFTX) buy
Jones Trading maintained its buy rating on Definium Therapeutics, Inc. with a $74 price target, a 64.63% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Jones Trading rated Definium Therapeutics, Inc. ($DFTX) "buy" with a $74 price target on June 24, 2026.
Since the rating, $DFTX is up 3.0% after 1 week, up 2.5% after 1 month and down 23.8% to date (from the $42.13 close on Jun 24, 2026).
DFTX
Definium Therapeutics, Inc.
Key Points
- Jones Trading reiterated its buy rating on Definium Therapeutics, Inc. (DFTX) with a $74 price target on June 24, 2026.
- Jones Trading's $74 price target implies 64.63% upside from Definium Therapeutics, Inc.'s ($DFTX) current $44.95 share price.
- Shares of NasdaqGS:DFTX traded near $36.18 on Wednesday, with a market cap of about $4 billion and a 52-week high of $39.16.
- Insiders, including CEO Robert Barrow, acquired shares recently, and analysts have consistently rated the stock as a strong buy.
Get $DFTX trade alerts by text
We text you when insiders, Congress or big funds trade $DFTX. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Definium Therapeutics, Inc. alert may contain errors. Disclosures
On June 24, 2026, Jones Trading reiterated its buy rating on Definium Therapeutics, Inc. (NasdaqGS: DFTX) with a price target of $74. The analyst, Justin Walsh, maintained a positive outlook on the stock, which traded at $36.18 on Wednesday.
Jones Trading vs. the S&P 500
Hypothetical returns from Jones Trading's disclosed trades, not real profit or advice. How we model this.
Definium Therapeutics, Inc. Stock Up 15.8%
Shares of Definium Therapeutics, Inc. traded near $36.18 on Wednesday. The company has a market capitalization of approximately $4 billion. Despite not being profitable, with a forward P/E ratio of -23.2, Definium's stock has been volatile, with a 52-week low of $6.35 and a high of $39.16. The stock's 50-day moving average is $22.61, and its 200-day moving average is $16.28. The company boasts a strong liquidity position, with current and quick ratios around 4.6, and a debt-to-equity ratio of 14.6.
$DFTX price target
Definium Therapeutics, Inc. daily closes and this analyst's $74 target. Not advice.
Insider Buying and Selling at Definium Therapeutics, Inc.
On June 22, 2026, several insiders at Definium Therapeutics, including CEO Robert Barrow and other top executives, acquired shares of the company. Barrow purchased 375,000 shares, while executives such as Chief Medical Officer Daniel Karlin and Chief Legal Officer Mark Sullivan each bought 62,500 shares. These transactions were not under any pre-planned trading agreements.
Analysts Set New Price Targets
Jones Trading maintained its buy rating on Definium Therapeutics with a $74 price target on June 24, 2026. Other firms have also shown optimism: Baird and Needham both reiterated buy ratings with targets of $57 and $50, respectively, on June 23, 2026. Leerink Partners and Oppenheimer echoed this sentiment with buy ratings and targets of $52 and $60 on June 22, 2026. The consensus among 15 analysts is a strong buy, with a mean price target of $39.87.
About Definium Therapeutics
Definium Therapeutics, Inc. is a biotechnology company based in New York, NY, specializing in developing therapies for brain health disorders. Led by CEO Robert Barrow, the company is advancing its lead product candidates, including DT120, in phase 3 trials for anxiety and depression, and DT402, in phase 2a trials for autism spectrum disorder. The company, formerly known as Mind Medicine (MindMed) Inc., rebranded to Definium Therapeutics in January 2026 and employs about 105 people.
Bottom Line
Definium Therapeutics continues to garner positive attention from analysts, with Jones Trading maintaining a buy rating and a $74 target. This aligns with insider confidence reflected in recent share purchases by top executives. Investors watch these developments closely, though it's important to remember that analyst ratings can be forward-looking and are not guarantees of future performance.
Related Filing Alerts
Source: Jones Trading's rating change on $DFTX (Jun 24, 2026). Written by software, not financial advice. How we make alerts